{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040057","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.214445+00:00","generated_at":"2026-06-08T08:18:42.494439+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lineage Cell Q3 rev $1.2M, net loss $7.1M; OpRegen Phase 2a enrolling","bullets":["Revenue $1.2M, down 60% YoY from $3.0M; net loss $7.1M ($0.04/sh) vs $6.1M ($0.04/sh) prior year.","Cash $41.3M, expected to fund operations into Q1 2025.","OpRegen Phase 2a in GA secondary to AMD enrolling under Genentech; new data showed rapid retinal structural improvements within 3 months in 5 patients.","On track to submit OPC1 IND amendment in Q4 2023 for spinal cord injury DOSED study.","Initiated hypoimmune pluripotent cell line development with Eterna Therapeutics; selected B2M deletion, HLA-E insertion, and third undisclosed edit."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040057","json":"https://secwatch.observer/filing/0001493152-23-040057.json","markdown":"https://secwatch.observer/filing/0001493152-23-040057.md","text":"https://secwatch.observer/filing/0001493152-23-040057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315223040057/0001493152-23-040057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315223040057/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:18:42.494439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d31d603b3f941bd43b59dcd2eccbe4c863fb1f6c","claim":"Lineage Cell Therapeutics, Inc. reported the three months ended September 30, 2023 results: revenue $1.2 milli.","evidence_excerpt":"revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2023 were $1.2 milli","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000149315223040057/0001493152-23-040057-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Revenue","value":"$1.2 milli"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}